Literature DB >> 8408652

Interaction of human beta 1 thyroid hormone receptor and its mutants with DNA and retinoid X receptor beta. T3 response element-dependent dominant negative potency.

C A Meier1, C Parkison, A Chen, K Ashizawa, S C Meier-Heusler, P Muchmore, S Y Cheng, B D Weintraub.   

Abstract

Mutations in the human beta thyroid hormone receptor (h-TR beta) gene are associated with the syndrome of generalized resistance to thyroid hormone. We investigated the interaction of three h-TR beta 1 mutants representing different types of functional impairment (kindreds ED, OK, and PV) with different response elements for 3,3',5-triiodothyronine (T3) and with retinoid X receptor beta (RXR beta). The mutant receptors showed an increased tendency to form homodimers on a palindromic T3-response element (TREpal), a direct repeat (DR + 4), and an inverted palindrome (TRElap). On TRElap, wild type TR binding was decreased by T3, while the mutant receptors showed a variably decreased degree of dissociation from TRElap in response to T3. The extent of dissociation was proportional to their T3 binding affinities. RXR beta induced the formation of h-TR beta 1:RXR beta heterodimers equally well for mutants and the wild type h-TR beta 1 on these T3 response elements. However, the T3-dependent increase in heterodimerization with RXR beta was absent or reduced for the mutant TRs. Transient transfection studies indicated that the dominant negative potency was several-fold more pronounced on the TRElap as compared to TREpal or DR + 4. In CV-1 and HeLa cells, transfection of RXR beta could not reverse the dominant negative action. These results demonstrate that the binding of mutant h-TRs to DNA, as well as their dominant negative potency, are TRE dependent. In addition, competition for DNA binding, rather than for limiting amounts of RXR beta, is likely to mediate the dominant negative action.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8408652      PMCID: PMC288366          DOI: 10.1172/JCI116793

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  The C'-terminal interaction domain of the thyroid hormone receptor confers the ability of the DNA site to dictate positive or negative transcriptional activity.

Authors:  J M Holloway; C K Glass; S Adler; C A Nelson; M G Rosenfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  Thyroid hormone receptor mutations that interfere with transcriptional activation also interfere with receptor interaction with a nuclear protein.

Authors:  A L O'Donnell; E D Rosen; D S Darling; R J Koenig
Journal:  Mol Endocrinol       Date:  1991-01

3.  v-erbA oncogene activation entails the loss of hormone-dependent regulator activity of c-erbA.

Authors:  M Zenke; A Muñoz; J Sap; B Vennström; H Beug
Journal:  Cell       Date:  1990-06-15       Impact factor: 41.582

4.  Tight linkage between the syndrome of generalized thyroid hormone resistance and the human c-erbA beta gene.

Authors:  S J Usala; A E Bale; N Gesundheit; C Weinberger; R W Lash; F E Wondisford; O W McBride; B D Weintraub
Journal:  Mol Endocrinol       Date:  1988-12

Review 5.  Interactions among a subfamily of nuclear hormone receptors: the regulatory zipper model.

Authors:  B M Forman; H H Samuels
Journal:  Mol Endocrinol       Date:  1990-09

6.  Modular structure of a chicken lysozyme silencer: involvement of an unusual thyroid hormone receptor binding site.

Authors:  A Baniahmad; C Steiner; A C Köhne; R Renkawitz
Journal:  Cell       Date:  1990-05-04       Impact factor: 41.582

7.  Dominant negative transcriptional regulation by a mutant thyroid hormone receptor-beta in a family with generalized resistance to thyroid hormone.

Authors:  A Sakurai; T Miyamoto; S Refetoff; L J DeGroot
Journal:  Mol Endocrinol       Date:  1990-12

8.  Generalized resistance to thyroid hormone associated with a mutation in the ligand-binding domain of the human thyroid hormone receptor beta.

Authors:  A Sakurai; K Takeda; K Ain; P Ceccarelli; A Nakai; S Seino; G I Bell; S Refetoff; L J DeGroot
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

9.  Thyrotropin-releasing hormone regulation of human TSHB expression: role of a pituitary-specific transcription factor (Pit-1/GHF-1) and potential interaction with a thyroid hormone-inhibitory element.

Authors:  H J Steinfelder; P Hauser; Y Nakayama; S Radovick; J H McClaskey; T Taylor; B D Weintraub; F E Wondisford
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

10.  Negative and positive transcriptional regulation by thyroid hormone receptor isoforms.

Authors:  A Rentoumis; V K Chatterjee; L D Madison; S Datta; G D Gallagher; L J Degroot; J L Jameson
Journal:  Mol Endocrinol       Date:  1990-10
View more
  18 in total

1.  The orphan nuclear receptor Ear-2 is a negative coregulator for thyroid hormone nuclear receptor function.

Authors:  X G Zhu; K S Park; M Kaneshige; M K Bhat; Q Zhu; C N Mariash; P McPhie; S Y Cheng
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

2.  A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone.

Authors:  T N Collingwood; R Wagner; C H Matthews; R J Clifton-Bligh; M Gurnell; O Rajanayagam; M Agostini; R J Fletterick; P Beck-Peccoz; W Reinhardt; G Binder; M B Ranke; A Hermus; R D Hesch; J Lazarus; P Newrick; V Parfitt; P Raggatt; F de Zegher; V K Chatterjee
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

3.  Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors.

Authors:  A Dace; L Zhao; K S Park; T Furuno; N Takamura; M Nakanishi; B L West; J A Hanover; S Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

Review 4.  Nomenclature of thyroid hormone receptor beta gene mutations in resistance to thyroid hormone. First workshop on thyroid hormone resistance, July 10-11, 1993, Cambridge, U.K.

Authors:  P Beck-Peccoz; V K Chatterjee; W W Chin; L J DeGroot; J L Jameson; H Nakamura; S Refetoff; S J Usala; B D Weintraub
Journal:  J Endocrinol Invest       Date:  1994-04       Impact factor: 4.256

5.  Phosphorylation enhances the target gene sequence-dependent dimerization of thyroid hormone receptor with retinoid X receptor.

Authors:  M K Bhat; K Ashizawa; S Y Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

6.  Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression.

Authors:  Hao Ying; Fumihiko Furuya; Li Zhao; Osamu Araki; Brian L West; John A Hanover; Mark C Willingham; Sheue-Yann Cheng
Journal:  J Clin Invest       Date:  2006-10-12       Impact factor: 14.808

7.  Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors.

Authors:  Changxue Lu; Mark C Willingham; Fumihiko Furuya; Sheue-Yann Cheng
Journal:  Endocrinology       Date:  2008-03-20       Impact factor: 4.736

8.  Mutations of CpG dinucleotides located in the triiodothyronine (T3)-binding domain of the thyroid hormone receptor (TR) beta gene that appears to be devoid of natural mutations may not be detected because they are unlikely to produce the clinical phenotype of resistance to thyroid hormone.

Authors:  Y Hayashi; T Sunthornthepvarakul; S Refetoff
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

9.  Genetic analysis of 29 kindreds with generalized and pituitary resistance to thyroid hormone. Identification of thirteen novel mutations in the thyroid hormone receptor beta gene.

Authors:  M Adams; C Matthews; T N Collingwood; Y Tone; P Beck-Peccoz; K K Chatterjee
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 10.  The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.

Authors:  Motoyasu Saji; Matthew D Ringel
Journal:  Mol Cell Endocrinol       Date:  2009-11-06       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.